Background
==========

Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous disorder characterised by progressive spasticity, weakness and hyperreflexia of the lower limbs. Clinically it is divided into a \'pure\' or uncomplicated form with progressive spasticity as major symptom, associated with brisk reflexes, muscle weakness, positive Babinski\'s sign and urinary urgency as well as a \'complicated\' form accompanied with other neurological abnormalities, i.e. retinal pigmentation, mental retardation, deafness, optic atrophy or seizures \[[@B1],[@B2]\]. So far, over 35 loci have been identified for autosomal dominant, recessive and X-linked HSP. The autosomal dominant HSP is indeed the main mode of inheritance, accounting for about 70--80% of all HSPs in Western countries, and it is predominantly associated with pure forms \[[@B1]\]. The occurrence of recessive HSP amount to 20--30%, whereas X-linked HSP is very rare.

In 15--40% of families with the \'pure\' autosomal dominant form of HSP, DNA sequence analysis identified a mutation in the *SPG4*gene (spastin) \[[@B1]\] and in \~10% a mutation in the *SPG3A*gene (atlastin) \[[@B2]\]. In further 18--20% of families gross deletions (of one or more exons) of the *SPG4*gene have been found \[[@B3],[@B4]\]. No pathogenic gross deletions in the *SPG3A*gene have been demonstrated so far. Mutations in the *REEP1*gene (SPG31) were analysed in two studies \[[@B5],[@B6]\], and pathogenic mutations were identified in 6.5% and 3% of cases, respectively, including one large multi-exonic duplication \[[@B5],[@B6]\].

Methods
=======

Subjects
--------

162 unrelated patients with clinical symptoms of \'pure\' HSP and a positive family history (at least two persons per family presented symptoms) were analysed in this study. Mutations in the *SPG4*gene were excluded in all patients and in *SPG3A*in 152 of the 162 patients. Gross deletions were excluded in half of the patients by MLPA. Control samples from 170 healthy German blood donors were collected at the Department of transfusion medicine of the University Hospital in Essen (Germany). DNA was extracted from EDTA-anticoagulated peripheral blood by using a standard salting-out method \[[@B7]\]. This study was approved by the institutional review board, informed consent was obtained from all subjects, and the Declaration of Helsinki protocols were followed.

PCR
---

Screening of the entire coding region of the *REEP1*gene (seven exons including the flanking intronic sequence, at least 40 bp from each end) was performed using polymerase chain reaction (PCR) with consecutive DHPLC analysis. PCR reactions for exon 1 were performed in a total volume of 10 μl, containing 60 ng DNA, 10 mmol of each dNTP DEAZA (Roche, Mannheim, Germany), 3 mmol MgCl~2~(Qiagen, Hilden, Germany) 10 pmol of each primer, 0.25 U Taq polymerase Hotstar Taq Plus (Qiagen, Hilden, Germany), DMSO 5% and 10 × buffer (contains 15 mM MgCl~2~); (Qiagen, Hilden, Germany). PCR reactions for exons 2 to 7 were performed in a total volume of 12.5 μl, containing 100 ng DNA, 2.5 mmol of each dNTP, 2 mmol MgCl~2~, 10 pmol of each primer, 0.5 U Taq polymerase (Genecraft, Lüdinghausen, Germany) and 10 × buffer BioTherm without MgCl~2~(Genecraft, Lüdinghausen, Germany). Thermal cycling was performed in a Biometra TGradient (Whatman, Maidstone, Kent, England). For each of the 7 PCR fragments, primer sequences and annealing temperatures are shown in Table [1](#T1){ref-type="table"}.

###### 

Primer sequences and annealing temperatures

  -------------------------------------------------------------------
  \                   \                              Annealing\
  Amplified segment   Primer                         temperature
  ------------------- ------------------------------ ----------------
  *SPG31*Ex 1         F1: ACCAGCTCACCGCCCAATC\       56°C/30 cycles
                      R1: GTATTAATAGCCCGAGCCACTGG    

  *SPG31*Ex 2         F2: AAGATAGAGGTGCCCAAGGATG\    58°C/28 cycles
                      R2: TGAGAACTGTGATGAAGGAACTCC   

  *SPG31*Ex 3         F3: GGAAGGATAGGGAGAAGGCTAC\    58°C/28 cycles
                      R3: CCTGAGGTGAGGTTTGAGGC       

  *SPG31*Ex 4         F4: TTCAAAAGGGCAGTGTTGCTG\     58°C/28 cycles
                      R4: ATGACTTGCTGGAGGCAAATGA     

  *SPG31*Ex 5         F5: GCCAAGCCCAATGCTCAGAG\      60°C/28 cycles
                      R5: GGTCCTTAGCCTGTTCTGTGTGG    

  *SPG31*Ex 6         F6: AGCTCCCTCTTGGCCTTTGTC\     58°C/28 cycles
                      R6: GGACTGGGCCTCTCTCAATGA      

  *SPG31*Ex 7         F7: GAGATTCAGGGAGACCCCAGC\     60°C/28 cycles
                      R7: GGAGAGAGAAAAGGCCATGTTTG    
  -------------------------------------------------------------------

(F: forward primer; R: reverse primer)

DHPLC analyses
--------------

DHPLC is a chromatographic mutation analysis technique that is based on temperature-dependent separation of DNA from PCR-amplified DNA fragments \[[@B8]\]. Different schemes for mutation screening were performed using DHPLC, i.e. the WAVE^®^DNA Fragment Analysis System (Transgenomic, Glasgow, UK) as described \[[@B9]\] with the analysis software Navigator Software (Transgenomic, Glasgow, UK).

PCR mixes were applied in double and four-fold amount (conditions see above) and were performed in total volumes of 25 μl (exons 2 to 7) or 40 μl (exon 1). Additionally the PCR amplicons were heated up to 94°C for 3 min and cooled slowly down to 20°C (30 sec) in a thermocycler (Biometra TGradient, Whatman, Maidstone, Kent, England) before loading onto the WAVE column. The amount of one injection per PCR sample was 5 μl. The probes were analyzed with variable retention times (Table [2](#T2){ref-type="table"}) and compared to a chromatogram of a healthy control sequence variation. A variant in exon 3 (c.164C\>A, p.Thr55Lys) was genotyped using the WAVE analysis system (no restriction enzyme available).

###### 

WAVE conditions

  Amplified segment   WAVE: oven temperature   time shift
  ------------------- ------------------------ ------------
  *SPG31*exon 1       65°C/70°C                no
  *SPG31*exon 2       54,5°C/57°C/58°C         no
  *SPG31*exon 3       59°C/63°C                63°C: 2,0
  *SPG31*exon 4       56°C/57°C/59°C           59°C: 1,0
  *SPG31*exon 5       58°C/61,5°C/64°C         no
  *SPG31*exon 6       61°C/62°C/63°C           no
  *SPG31*exon 7       58,6°C/60,6°C            no

DNA sequencing
--------------

DNA samples with peculiar separation behaviour in DHPLC analysis were directly sequenced using the AMPure- (1^st^purification) and CleanSeq-Kit (2^nd^-purification; Beckman, Krefeld, Germany) as described in the manufacturer\'s instructions on an automated sequencer (MegaBace 1000, GE Healthcare, Freiburg, Germany; and ABI PRISM 377, DNA Sequencer).

RFLP
----

Two newly identified sequence variations, c.320T\>C, p.Leu107Pro (exon 5) and c.105+6T\>C (intron 2), as well as a mutation in the 3\'UTR (c.606+43G\>T) were genotyped by restriction enzyme digestion. Patient and control samples were amplified using the same primers and conditions as described above. 12.5 μl of PCR products were digested with 0.31 units of Bbv I (intron 2), 0.25 units of Msp I (exon 5) and 0.46 units of BsuRI (3\'UTR) at 37°C for 3 hours. The fragments were separated on 2% agarose gels in 1 × TBE buffer (30 min, 200 V) and visualised using ethidium bromide.

*In silico*analysis
-------------------

Putative functional and splicing effects of the three unclear sequence variations were investigated using the programs ESEfinder release 3.0 \[[@B10]\] and NNSPLICE 0.9 software \[[@B11]\]. ESEfinder identifies putative exon splicing enhancers responsive to the human SR proteins SF2/ASF, SC35, SRp40 and SRp55. NNSPLICE is based on a neural network to predict the presence and relative efficiencies of donor and acceptor sites.

Results and Discussion
======================

In this study we analysed a cohort of 162 patients with the \'pure\' autosomal-dominant form of HSP for mutations in the *REEP1*gene. In addition, 170 healthy control subjects were analysed for the newly identified sequence variations.

We identified nucleotide exchanges in all exons in comparison to the reference sequence except for exon 1. Ten mutations which include 7 (4.3% of cases) pathogenic mutations (small insertions/deletions, nonsense- and 3\'UTR exchanges) and three (1.9% of cases) novel sequence variations (missense and splice site) were identified. Six of these seven pathogenic mutations (three small out of frame deletions, two small out of frame insertion and a nonsense mutation) as well as three unclear sequence variations (two missense and one splice site) have not been described before (Table [3](#T3){ref-type="table"}). In detail, we newly identified two small deletions of one nucleotide (c.60delG and c.478delA), one deletion of eight nucleotides (c.340_347delAGTTACGA), an insertion of one nucleotide (c.419_420insG), an insertion of two nucleotides (c.183_184insCT) and a nucleotide exchange which leads to a premature stop codon (c.C345A; p.Try115X). Because DHPLC mutation screening technique is not 100% sensitive \[[@B12]\], sequence alterations might be missed, which would increase the frequency of *REEP1*mutations. In three cases more than one symptomatic family member was analysed. There was one more family member tested for the deletions in exon 6 (c.478delA) and in exon 2 (c.60delG) in each case and two additional family members for the insertion (c.419_420insG). The three families are composed of father and son, father and daughter as well as mother and two children. All affected family members show the same mutation. In our HSP cohort the mean age of onset is in the early twenties (3 to 50 years). Two novel variations represent missense mutations (c.164C\>A, p.Thr55Lys, c.320T\>C, p.Leu107Pro) and the other one a splice site variation in the donor splice site (c.105+6 T\>C). The splice site prediction program NNSPLICE 0.9 calculates a score of 0.98 for the wild-type donor of exon/intron 2. The c.105+6 T\>C substitution lowers the donor consensus value to 0.88, probably leading to preferential usage of a cryptic donor present 29 bp downstream in intron 2 with a score of 0.64 \[gagtcagGTcaggtg\].

###### 

Mutations found in *REEP1*

                  Nucleotide exchange    Amino acid exchange
  --------------- ---------------------- ---------------------
  *SPG31*exon 1   none                   
  *SPG31*exon 2   c.60delG               p.6fsX
                  c.105+6T\>C            
  *SPG31*exon 3   c.164C\>A              p.Thr55Lys
  *SPG31*exon 4   c.183_184insCT         p.7fsX
  *SPG31*exon 5   c.320T\>C              p.Leu107Pro
                  c.340_347delAGTTACGA   p.69fsX,
                  c.345C\>A              p.Try115X
  *SPG31*exon 6   c.419_420insG          p.45fsX
                  c.478delA              p.62fsX
  *SPG31*exon 7   c.606+43G\>T\*         

\* previously described

*In silico*analysis with the ESE-finder program revealed that c.164C\>A abolishes strong exon splicing enhancer sites for SF2/ASF, SRp40 and SRp55 as well as it leads to a new strong site for SRp55. For c.320T\>C the score for a potential binding site for the splicing factors SRp40 strongly increases when substituting the T by C. Thus these sequence exchanges could result in defective splicing of introns, exon skipping, frameshift and introduction of another premature termination codon. In that case, all sequence variations found would be in line with the concept of haploinsufficiency. Unfortunately, we could not test this hypothesis, because, as *REEP1*is not expressed in peripheral blood cells \[[@B6]\], we were not able to perform RNA analyses. Furthermore, we also had no further relatives with symptoms of HSP available to be investigated. Segregation analysis for these sequence variations is advisable in order to confirm the pathogenetic relevance. Yet, all unclear sequence variations were absent in 170 healthy controls.

In addition, we identified also common polymorphisms in exon 2 to exon 5 in many cases, which are listed in Table [4](#T4){ref-type="table"}. Additionally, we found two further polymorphisms in intron 6 (c.595T\>G) and the 3\'UTR (c.606+155T\>C) in four of the 162 patients in heterozygous state (allele frequency 1.2%).

###### 

Polymorphisms found in *REEP1*

                    rs-number/Polymorphism
  ----------------- -------------------------------
  *SPG31*intron 1   rs1863059
  *SPG31*intron 2   rs1863058
                    rs1863056
  *SPG31*exon 4     rs2276625
  *SPG31*intron 5   rs12988844
  *SPG31*intron 6   c.595-19T\>G, G allele: 1,2%
  *SPG31*3\'UTR     c.606+155T\>C, C allele: 1,2%

Conclusion
==========

Having identified pathogenic mutations in the *REEP1*gene in 4.3% of our HSP cases, previous mutation frequency determinations (6.5% and 3%, respectively) are substantiated, and hence the spectrum of *REEP1*mutations is complemented. Mutations in the *REEP1*gene appear as the third most frequent cause in families with the \'pure\' autosomal dominant form of HSP. Therefore mutation analysis in the *REEP1*gene should be included in the comprehensive care for patients with the \'pure\' autosomal dominant form of HSP.
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